Document is current
Any future updates will be listed below
-
Authors
Shibata, Nobuhiro https://orcid.org/0000-0001-8647-5098
Kuwazawa, Hiroshi
Yasukawa, Tomoharu
Iwabuchi, Manabu
Saji, Shigehira https://orcid.org/0000-0002-6732-8030
-
Funding
Funding for this research was provided by:
Kyowa Kirin Co., Ltd., Tokyo, Japan
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 11 October 2025
First Online: 22 November 2025
Declarations
:
: This survey was conducted in compliance with the Ministerial Ordinance on Post-Marketing Surveillance and Testing of Drugs (GPSP) in Japan (Ministry of Health, Labour and Welfare Ordinance No. 171 dated December 20, 2004) upon approval of the heads of each institution. All institutions that provided the data agreed for the survey results to be published.
: A post-marketing surveillance study is exempt from obtaining informed consent by the ordinance.
: NS received consulting fees for serving on the advisory board from Kyowa Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd.; honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Merck Biopharma Co., Ltd., and Bristol-Myers Squibb K.K.; and research funding from Daiichi Sankyo Co., Ltd. MSD K.K., and AstraZeneca K.K. SS received lecture fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Novartis Pharma K.K., Eisai Co., Ltd., Takeda Pharmaceutical Company Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., AstraZeneca K.K., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Gilead Sciences, Inc., Exact Sciences K.K. and research grants from Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., MSD K.K., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Eli Lilly Japan K.K., Sanofi K.K.; had an advisory role for Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K.; and was an executive board member of JBCRG (Japan Breast Cancer Research Group), JBCS (Japan Breast Cancer Society), JSMO (Japanese Society of Medical Oncology) and BIG (Breast International Group). HK, TY, and MI are employees of Kyowa Kirin Co., Ltd.
